FDA Proposes Higher User Fees for Overseas Phase I Trials to Boost Domestic Drug Development
核心洞察
The FDA is proposing to raise user fees for companies conducting Phase I clinical trials outside the U.S. while reducing fees for domestic programs to incentivize American drug development.
The proposal aims to "anchor clinical development in the United States" as part of Commissioner Marty Makary's "America-first agenda" amid concerns about losing biopharma R&D leadership to countries like China.
Industry representatives questioned why the FDA chose fee restructuring over efficiency improvements to accelerate drug development timelines, with specific implementation details to be determined in future negotiations.
The FDA is proposing to restructure its user fee system to penalize companies conducting Phase I clinical trials outside the United States while offering reduced fees for domestic programs, according to meeting minutes from November 6 negotiations between the agency and industry representatives.
Under the proposal, "programs that do not conduct Phase 1 clinical trials in the U.S. would experience higher fees," FDA officials told industry groups including the Biotechnology Innovation Organization (搜索), Pharmaceutical Research and Manufacturers of America (搜索), and Consumer Healthcare Products Association (搜索). The agency stated this approach will help "anchor clinical development in the United States."
Strategic Response to Global Competition
The fee restructuring represents part of what Commissioner Marty Makary has termed the FDA's "America-first agenda," addressing concerns about the U.S. losing its position in biopharma R&D to other countries, particularly China, which has emerged as a major source of new therapeutic candidates in recent years.
"If your Phase I trial is not in the United States, maybe you should pay a higher user fee," Makary said during a recent speech at a National Academies of Sciences, Engineering, and Medicine (搜索) workshop.
The proposal would not only raise user fees for overseas programs that exclude U.S. Phase I trials but would also introduce additional annual fees after an Investigational New Drug (IND) application is filed.
Industry Pushback and Implementation Questions
Industry representatives challenged the FDA's approach, asking why the agency was focusing on user fees rather than introducing "efficiencies that could accelerate the time required for drug development and review." The FDA acknowledged such measures are "of interest" but fall "outside the scope of the user fee negotiations."
Companies also sought clarification on implementation details, including criteria for reduced application fees, timing of fee payments, and the impact on small and midsize companies. FDA officials were unable to provide specifics, noting that the agency "agreed to propose a plan for future discussions about the fee incentives proposal."
PDUFA VIII Negotiations Context
The discussions are part of ongoing negotiations for the eighth cycle of the FDA's prescription drug user fee program (PDUFA VIII), scheduled to begin October 1, 2027. User fee programs accounted for nearly half of the FDA's overall $47 billion budget in 2024 and are authorized in five-year blocks.
The November meeting marked the end of the first week of talks between the FDA and industry. Commissioner Makary has previously expressed support for reduced user fees overall, arguing this would make it easier for smaller companies to advance promising programs into clinical development.
Historical Impact of User Fee System
The PhRMA (搜索) industry organization has emphasized the PDUFA system's importance to American drug development leadership. According to the group, 70% of medicines were approved first in other countries before PDUFA's introduction, while now 70% are cleared first in the U.S.
The user fee system allows the FDA to collect payments from drugmakers seeking product reviews, with fees providing companies certain performance standards including turnaround times and guaranteed access to regulatory meetings, though payment does not guarantee approval.